Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | MEVPRO trials: investigating EZH2 inhibitors in mCRPC

Michael Schweizer • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer Abiraterone
MEVPRO-1 MEVPRO-2

Michael Schweizer, MD, Fred Hutchinson Cancer Center, Seattle, WA, describes ongoing trials evaluating enhancer of zeste homolog 2 (EZH2) inhibitors in metastatic castration-resistant prostate cancer (mCRPC). The MEVPRO-2 (NCT06629779) trial is testing these inhibitors in androgen receptor pathway inhibitor (APRI)-naïve patients, while the MEVPRO-1 (NCT06551324) trial focuses on patients who previously progressed on abiraterone. These pivotal studies will determine the efficacy of EZH2 inhibitors and their potential role as a standard of care. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Schweizer

MEVPRO-2: mevrometostat and enzalutamide in patients with ARPI-naïve mCRPC
0:33
MEVPRO-2: mevrometostat and enzalutamide in patients with ARPI-naïve mCRPC
Michael Schweizer • 14 Feb 2025
Mevrometostat and enzalutamide in mCRPC: gene expression and EZH2 modulation
0:55
Mevrometostat and enzalutamide in mCRPC: gene expression and EZH2 modulation
Michael Schweizer • 14 Feb 2025
Early results of mevrometostat & enzalutamide in mCRPC at ASCO GU 2025
1:12
Early results of mevrometostat & enzalutamide in mCRPC at ASCO GU 2025
Michael Schweizer • 14 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals